RFA
CUE icon

Reilly Financial Advisors’s Cue Biopharma CUE Stock Holding History

Reilly Financial Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$2K Buy
+7
New +$2.71K ﹤0.01% 973

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Reilly Financial Advisors's CUE Position: Q4 2021 in Review

Reilly Financial Advisors opened a new position in Cue Biopharma (CUE) in Q4 2021: 7 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #973 among its holdings.

91 funds tracked by Wall St. Rank hold CUE as of Q4 2021.

  • Reilly Financial Advisors held 7 shares of Cue Biopharma worth $2K as of Q4 2021.
  • Cue Biopharma was a new Reilly Financial Advisors position in Q4 2021.
  • Cue Biopharma made up ﹤0.01% of Reilly Financial Advisors's portfolio in Q4 2021, its #973 holding.
  • 91 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2021.

Based on Reilly Financial Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.